Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -13.30% is 73% above its 5-year average of -49.16%, around the middle of its 5-year range (-295.49%–639.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 2054.00% below its 12-month average of -0.62%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -13.30%.
RETURN ON EQUITY (ROE)
-13.30%
RETURN ON EQUITY (ROE) AVG TTM
-0.62%
RETURN ON EQUITY (ROE) AVG 3Y
2.98%
RETURN ON EQUITY (ROE) AVG 5Y
-49.16%
RETURN ON EQUITY (ROE) AVG 10Y
-49.14%
RETURN ON EQUITY (ROE) AVG 15Y
-40.67%
RETURN ON EQUITY (ROE) AVG 20Y
-35.72%
CURRENT VS TTM AVG
-2054.00%
CURRENT VS 3Y AVG
-545.93%
CURRENT VS 5Y AVG
+72.95%
CURRENT VS 10Y AVG
+72.94%
CURRENT VS 15Y AVG
+67.30%
CURRENT VS 20Y AVG
+62.77%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+68.35%
vs the sector median at left
Gyre Therapeutics, Inc.
Market Cap
$788.23M
Return on Equity (ROE)
-13.30%
TTM Avg
-0.62%
3Y Avg
2.98%
5Y Avg
-49.16%
Market Cap
$781.63M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$777.59M
Return on Equity (ROE)
4.45%
TTM Avg
-14.88%
3Y Avg
-5.15%
5Y Avg
-1.23%
Market Cap
$775.02M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
Market Cap
$775.12M
Return on Equity (ROE)
-35.02%
TTM Avg
-92.06%
3Y Avg
-115.35%
5Y Avg
-96.02%
Market Cap
$802.34M
Return on Equity (ROE)
-34.83%
TTM Avg
-64.71%
3Y Avg
-59.77%
5Y Avg
-96.53%
Market Cap
$803.27M
Return on Equity (ROE)
12.32%
TTM Avg
19.75%
3Y Avg
23.44%
5Y Avg
27.16%
Market Cap
$771.17M
Return on Equity (ROE)
-137.04%
TTM Avg
-129.13%
3Y Avg
-102.69%
5Y Avg
-65.31%
Market Cap
$810.26M
Return on Equity (ROE)
-37.38%
TTM Avg
-29.74%
3Y Avg
-41.86%
5Y Avg
-72.28%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $788.23M | -13.30% | -0.62% | 2.98% | -49.16% |
| AdaptHealth Corp. (AHCO)vs › | $781.63M | -16.56% | 0.55% | -10.56% | -13.37% |
| Varex Imaging Corporation (VREX)vs › | $777.59M | 4.45% | -14.88% | -5.15% | -1.23% |
| Geron Corporation (GERN)vs › | $775.02M | -31.97% | -50.13% | -87.97% | -79.93% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | -35.02% | -92.06% | -115.35% | -96.02% |
| Jade Biosciences, Inc. (JBIO)vs › | $802.34M | -34.83% | -64.71% | -59.77% | -96.53% |
| InMode Ltd. (INMD)vs › | $803.27M | 12.32% | 19.75% | 23.44% | 27.16% |
| Sana Biotechnology, Inc. (SANA)vs › | $771.17M | -137.04% | -129.13% | -102.69% | -65.31% |
| Ardelyx, Inc. (ARDX)vs › | $810.26M | -37.38% | -29.74% | -41.86% | -72.28% |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.35M | 2.54% | 1.18% | -43.07% | -28.50% |
ROE
-13.3%
ROA
-8.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -13.30% |
| 2026-03-31 | -6.05% |
| 2025-12-31 | 4.89% |
| 2025-09-30 | 6.68% |
| 2025-06-30 | 4.70% |
| 2025-03-31 | 10.64% |
| 2024-12-31 | 19.09% |
| 2024-09-30 | -140.59% |
| 2024-06-30 | -142.45% |
| 2024-03-31 | -154.74% |
| 2023-09-30 | 130.61% |
| 2023-06-30 | -2.79% |
| 2023-03-31 | 639.72% |
| 2022-12-31 | 71.21% |
| 2022-09-30 | 31.58% |
| 2022-06-30 | -10.71% |
| 2022-03-31 | -295.49% |
| 2021-12-31 | -214.01% |
| 2021-09-30 | -142.44% |
| 2021-06-30 | -90.77% |
| 2021-03-31 | -71.69% |
| 2020-12-31 | -73.93% |
| 2020-09-30 | -54.16% |
| 2020-06-30 | -43.70% |
| 2020-03-31 | -45.27% |
| 2019-12-31 | -80.75% |
| 2019-09-30 | -64.48% |
| 2019-06-30 | -50.90% |
| 2019-03-31 | -37.89% |
| 2018-12-31 | -25.06% |
| 2018-09-30 | -19.22% |
| 2018-06-30 | -16.84% |
| 2018-03-31 | -15.73% |
| 2017-12-31 | -70.06% |
| 2017-09-30 | -78.60% |
| 2017-06-30 | -61.08% |
| 2017-03-31 | -126.42% |
| 2016-12-31 | -105.44% |
| 2016-09-30 | -93.48% |
| 2016-06-30 | -79.24% |
| 2016-03-31 | -64.70% |
| 2015-12-31 | -67.68% |
| 2015-09-30 | -57.36% |
| 2015-06-30 | -20.67% |
| 2015-03-31 | -23.61% |
| 2014-12-31 | -29.91% |
| 2014-09-30 | -36.63% |
| 2014-06-30 | -42.22% |
| 2014-03-31 | -43.22% |
| 2013-12-31 | -34.70% |
| 2013-09-30 | -33.54% |
| 2013-06-30 | -27.93% |
| 2013-03-31 | -10.22% |
| 2012-12-31 | -3.98% |
| 2012-09-30 | -0.49% |
| 2012-06-30 | -1.07% |
| 2012-03-31 | -10.55% |
| 2011-12-31 | -4.89% |
| 2011-09-30 | -0.49% |
| 2011-06-30 | 5.63% |
| 2011-03-31 | 15.52% |
| 2010-12-31 | 11.87% |
| 2010-09-30 | -14.77% |
| 2010-06-30 | -16.85% |
| 2010-03-31 | -35.70% |
| 2009-12-31 | -57.11% |
| 2009-09-30 | -39.34% |
| 2009-06-30 | -61.96% |
| 2009-03-31 | -46.06% |
| 2008-12-31 | -44.73% |
| 2008-09-30 | -44.78% |
| 2008-06-30 | -39.84% |
| 2008-03-31 | -38.63% |
| 2007-12-31 | -54.42% |
| 2007-09-30 | -6.16% |
| 2007-06-30 | -2.05% |
| 2007-03-31 | 4.20% |
| 2006-12-31 | 3.23% |
| 2006-09-30 | -44.43% |
| 2006-06-30 | -44.48% |
